Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 13/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233478 | 0.88 | UTS2R (0.51) | UTS2RTAS1R3TAS1R1CNR2FAAH | |
| SCHEMBL916706 | 0.87 | UTS2R (0.51) | UTS2RCNR2POLBMAPTHPGD | |
| SCHEMBL637258 | 0.78 | SMN1; SMN2 (0.45) | MAPTHPGDLMNANPC1RAB9A | |
| SCHEMBL2231327 | 0.76 | UTS2R (0.47) | UTS2R | |
| SCHEMBL916705 | 0.74 | UTS2R (0.44) | UTS2RCNR2MAPTHPGDLMNA | |
| SCHEMBL637670 | 0.73 | UTS2R (0.45) | UTS2R | |
| SCHEMBL2230625 | 0.72 | UTS2R (0.40) | UTS2RLMNA | |
| SCHEMBL2476909 | 0.71 | TAS1R3 (0.64) | UTS2RTAS1R3TAS1R1 | |
| SCHEMBL2408633 | 0.71 | TAS1R3 (0.64) | UTS2RTAS1R3TAS1R1 | |
| SCHEMBL638040 | 0.71 | KMT2A (0.50) | POLBMAPTHPGDLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7572830-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-04-24 | — | — | US | disclosed |
| EP-1660440-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019163-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | UTS2R 1572/4885TAS1R3 1407/4885TAS1R1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.